Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

Topline data were announced from a trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Spironolactone is a diuretic (water pill) commonly used to treat heart failure and high blood pressure, but it can also be ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...

Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water. Normally ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.